Attention, concentration and fatigue in long-term conditions study: Participants who attend the testing session in London will be paid £20.00
Most of us have ‘goals’ - things that we want to achieve, and we think can be achieved with a bit of effort. However, sometimes we don’t make as much progress on our goals as we would like to. Sometimes things get in the way and other times we are not sure what we need to do to make progress. In...
Source Multiple News Today: A molecule responsible for preventing the repair of white matter in the brain, a process critical to treating multiple sclerosis (MS) and cerebral palsy, has been identified.
The research, “A TLR/AKT/FoxO3 immune-tolerance like pathway disrupts the repair...
Source Neurology Advisor: In patients with relapsing-remitting multiple sclerosis (RRMS), fingolimod may protect against deep gray matter (dGM) and thalamus volume loss and may also lead to slower disability progression compared with placebo, according to an analysis published in Neurology.
Source MS Society: Researchers at the MS Society Edinburgh Centre for MS Research have found that extra myelin can be sent to the wrong part of the nerve – an important insight for MS treatments.
Source MS Trust: The causes of MS are not well understood and there are a number of factors to be considered. You may wonder whether you did something to cause your MS or if you could have stopped MS from happening to you. The answer is 'no'. No one could have advised you how to prevent your MS.
Source Royal Holloway University: We are looking for volunteers with Relapsing Remitting MS to take part in a new study investigating the relationship between specific mental skills and employment in Multiple Sclerosis
Source BBC: MS drug hope for secondary-progressive stage. A study of a new drug to treat advanced cases of multiple sclerosis suggests it may be possible to delay progression of the disease in the short term, although the effects were small.
Source BBC: A year on from gruelling stem cell treatment for her multiple sclerosis, BBC correspondent Caroline Wyatt reveals what effect the potentially life-changing "reboot" of her immune system has had on her life.
Source MS Society:
Disease modifying therapy daclizumab (Zinbryta) has been withdrawn from sale worldwide. Its manufacturers took the decision after reports that a number of people taking the treatment developed serious inflammatory brain disorders.